Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The product will be launched by NATCO's commercial partner Viatris.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Subscribe To Our Newsletter & Stay Updated
